We do the right thing in the right way.
Our commitment to corporate citizenship is built on a foundation of integrity, quality and respect. These values provide solid footing for the creation and support of long-term programs that focus on patients, employees, the environment and our local communities.
We believe that future mRNA medicines will be Moderna’s biggest contribution to society. These innovations have the potential to create unique ways to treat and prevent diseases at a new breadth and scale.
Our mRNA platform has the potential to play an important role in supporting those working to meet the needs of underserved populations in order to aid in public health planning, and to be a resource in the event of potential public health crises.

Delivering on the promise of mRNA therapies for rare diseases
Dr. Stephen Hoge, Moderna President and Paolo Martini, Chief Scientific Officer discuss how Moderna is delivering on the promise of mRNA therapies for rare diseases.
The Framework
Moderna’s corporate responsibility strategy considers the needs and priorities of our key stakeholders and the five focus areas where we can have a positive impact today and in the future.
We’re focused on accelerating the development of safe and effective mRNA medicines for patients.
We will only accomplish our goals if we are able to attract and retain individuals of diverse backgrounds and of all ages, genders, ethnicities, religions, home countries and sexual orientations.
We seek to drive change through what we make and how we make it.
We’re active contributors to the communities where we work and live so that we can make a positive difference today and for decades to come.
The highest ethical standards are core to how we operate—from our clinical trials, manufacturing process and creation of high-quality investigational medicines, to how we conduct ourselves with employees, patients and other stakeholders.
Moderna in the Community

“We will continue to build upon and execute against all areas outlined in our CSR framework—an effort which I believe is critical to all our stakeholders, important to our employees and will be a key contributor in our efforts to bring new medicines to patients around the world.”
